{"entity":{"id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","aka":[],"tldr":"A phase 3 trial of AZD0486 in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.","summary":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) is a phase 3 interventional study registered as NCT07509151 by AstraZeneca, with 420 participants planned, started 2026-05-05 and due to reach its primary completion in 2031-08-29. Interventions recorded: Surovatamig. Conditions listed: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07509151","url":"https://clinicaltrials.gov/study/NCT07509151"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["azd0486"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07509151","phase":"3","setting":"A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)","sponsor":"AstraZeneca","enrolled":420,"outcomes":[]},"route":"/trials/nct07509151/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}